File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
  • Basic View
  • Metadata View
  • XML View
TitleSerum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
 
AuthorsZhang, X1
Yeung, DCY1
Karpisek, M5
Stejskal, D3
Zhou, ZG2
Liu, F6
Wong, RLC1
Chow, WS1
Tso, AWK1
Lam, KSL1 4
Xu, A1
 
Issue Date2008
 
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
 
CitationDiabetes, 2008, v. 57 n. 5, p. 1246-1253 [How to Cite?]
DOI: http://dx.doi.org/10.2337/db07-1476
 
AbstractOBJECTIVE-Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and insulin sensitivity in animal models. This study aimed to investigate the relationship between its serum levels and various cardiometabolic parameters in humans. RESEARCH DESIGN AND METHODS-A newly developed immunoassay was used to measure serum FGF21 levels in 232 Chinese subjects recruited from our previous cross-sectional studies. The mRNA expression levels of FGF21 in the liver and adipose tissues were quantified by real-time PCR. RESULTS-Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. Serum FGF21 correlated positively with adiposity, fasting insulin, and triglyc-erides but negatively with HDL cholesterol, after adjusting for age and BMI. Logistic regression analysis demonstrated an independent association between serum FGF21 and the metabolic syndrome. Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. Our in vitro study detected a differentiation-dependent expression of FGF21 in 3T3-L1 adipocytes and human adipocytes. In db/db obese mice, FGF21 mRNA expression was markedly increased in both the liver and adipose tissue compared with that in their lean littermates. Furthermore, FGF21 expression in subcutaneous fat correlated well with its circulating concentrations in humans. CONCLUSIONS-FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. © 2008 by the American Diabetes Association.
 
ISSN0012-1797
2013 Impact Factor: 8.474
2013 SCImago Journal Rankings: 4.749
 
DOIhttp://dx.doi.org/10.2337/db07-1476
 
ISI Accession Number IDWOS:000255628700014
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZhang, X
 
dc.contributor.authorYeung, DCY
 
dc.contributor.authorKarpisek, M
 
dc.contributor.authorStejskal, D
 
dc.contributor.authorZhou, ZG
 
dc.contributor.authorLiu, F
 
dc.contributor.authorWong, RLC
 
dc.contributor.authorChow, WS
 
dc.contributor.authorTso, AWK
 
dc.contributor.authorLam, KSL
 
dc.contributor.authorXu, A
 
dc.date.accessioned2010-09-06T07:23:56Z
 
dc.date.available2010-09-06T07:23:56Z
 
dc.date.issued2008
 
dc.description.abstractOBJECTIVE-Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and insulin sensitivity in animal models. This study aimed to investigate the relationship between its serum levels and various cardiometabolic parameters in humans. RESEARCH DESIGN AND METHODS-A newly developed immunoassay was used to measure serum FGF21 levels in 232 Chinese subjects recruited from our previous cross-sectional studies. The mRNA expression levels of FGF21 in the liver and adipose tissues were quantified by real-time PCR. RESULTS-Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. Serum FGF21 correlated positively with adiposity, fasting insulin, and triglyc-erides but negatively with HDL cholesterol, after adjusting for age and BMI. Logistic regression analysis demonstrated an independent association between serum FGF21 and the metabolic syndrome. Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. Our in vitro study detected a differentiation-dependent expression of FGF21 in 3T3-L1 adipocytes and human adipocytes. In db/db obese mice, FGF21 mRNA expression was markedly increased in both the liver and adipose tissue compared with that in their lean littermates. Furthermore, FGF21 expression in subcutaneous fat correlated well with its circulating concentrations in humans. CONCLUSIONS-FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. © 2008 by the American Diabetes Association.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationDiabetes, 2008, v. 57 n. 5, p. 1246-1253 [How to Cite?]
DOI: http://dx.doi.org/10.2337/db07-1476
 
dc.identifier.doihttp://dx.doi.org/10.2337/db07-1476
 
dc.identifier.eissn1939-327X
 
dc.identifier.epage1253
 
dc.identifier.f10001100340
 
dc.identifier.f10001100340
 
dc.identifier.f10001100340
 
dc.identifier.f10001100340
 
dc.identifier.f10001100340
 
dc.identifier.f10001100340
 
dc.identifier.hkuros140652
 
dc.identifier.isiWOS:000255628700014
 
dc.identifier.issn0012-1797
2013 Impact Factor: 8.474
2013 SCImago Journal Rankings: 4.749
 
dc.identifier.issue5
 
dc.identifier.openurl
 
dc.identifier.scopuseid_2-s2.0-48349146527
 
dc.identifier.spage1246
 
dc.identifier.urihttp://hdl.handle.net/10722/76693
 
dc.identifier.volume57
 
dc.languageeng
 
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofDiabetes
 
dc.relation.referencesReferences in Scopus
 
dc.titleSerum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhang, X</contributor.author>
<contributor.author>Yeung, DCY</contributor.author>
<contributor.author>Karpisek, M</contributor.author>
<contributor.author>Stejskal, D</contributor.author>
<contributor.author>Zhou, ZG</contributor.author>
<contributor.author>Liu, F</contributor.author>
<contributor.author>Wong, RLC</contributor.author>
<contributor.author>Chow, WS</contributor.author>
<contributor.author>Tso, AWK</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<contributor.author>Xu, A</contributor.author>
<date.accessioned>2010-09-06T07:23:56Z</date.accessioned>
<date.available>2010-09-06T07:23:56Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Diabetes, 2008, v. 57 n. 5, p. 1246-1253</identifier.citation>
<identifier.issn>0012-1797</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/76693</identifier.uri>
<description.abstract>OBJECTIVE-Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and insulin sensitivity in animal models. This study aimed to investigate the relationship between its serum levels and various cardiometabolic parameters in humans. RESEARCH DESIGN AND METHODS-A newly developed immunoassay was used to measure serum FGF21 levels in 232 Chinese subjects recruited from our previous cross-sectional studies. The mRNA expression levels of FGF21 in the liver and adipose tissues were quantified by real-time PCR. RESULTS-Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. Serum FGF21 correlated positively with adiposity, fasting insulin, and triglyc-erides but negatively with HDL cholesterol, after adjusting for age and BMI. Logistic regression analysis demonstrated an independent association between serum FGF21 and the metabolic syndrome. Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. Our in vitro study detected a differentiation-dependent expression of FGF21 in 3T3-L1 adipocytes and human adipocytes. In db/db obese mice, FGF21 mRNA expression was markedly increased in both the liver and adipose tissue compared with that in their lean littermates. Furthermore, FGF21 expression in subcutaneous fat correlated well with its circulating concentrations in humans. CONCLUSIONS-FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. &#169; 2008 by the American Diabetes Association.</description.abstract>
<language>eng</language>
<publisher>American Diabetes Association. The Journal&apos;s web site is located at http://diabetes.diabetesjournals.org/</publisher>
<relation.ispartof>Diabetes</relation.ispartof>
<title>Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0012-1797&amp;volume=&amp;spage=57(5):1246&amp;epage=53&amp;date=2008&amp;atitle=Serum+FGF21+levels+are+increased+in+obesity+and+are+independently+associated+with+the+metabolic+syndrome+in+humans</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.2337/db07-1476</identifier.doi>
<identifier.scopus>eid_2-s2.0-48349146527</identifier.scopus>
<identifier.hkuros>140652</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-48349146527&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>57</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>1246</identifier.spage>
<identifier.epage>1253</identifier.epage>
<identifier.eissn>1939-327X</identifier.eissn>
<identifier.isi>WOS:000255628700014</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.f1000>1100340</identifier.f1000>
<identifier.f1000>1100340</identifier.f1000>
<identifier.f1000>1100340</identifier.f1000>
<identifier.f1000>1100340</identifier.f1000>
<identifier.f1000>1100340</identifier.f1000>
<identifier.f1000>1100340</identifier.f1000>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Second Xiangya Hospital of Central-South University
  3. Sternberk Hospital
  4. The University of Hong Kong
  5. University of Veterinary and Pharmaceutical Sciences Brno
  6. UTHSTCSA